(a) Short title.—This Act may be cited as the “Cannabis Administration and Opportunity Act”.

(b) Table of contents.—The table of contents for this Act is as follows:

Sec. 1. Short title; table of contents.
Sec. 2. Findings.
Sec. 3. Definitions.

The Congress finds as follows:

(1) The communities that have been most harmed by cannabis prohibition are benefitting the least from the legal marijuana marketplace.

(2) A legacy of racial and ethnic injustices, compounded by the disproportionate collateral consequences of 80 years of cannabis prohibition enforcement, now limits participation in the industry.

(3) 38 States, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and Indian Tribes have adopted laws allowing legal access to cannabis, and 19 States, the District of Columbia, the Commonwealth of the Northern Mariana Islands, and Guam have adopted laws legalizing cannabis for adult recreational use.

(4) A total of 49 States have reformed their laws pertaining to cannabis despite the Schedule I status of marijuana and its Federal criminalization.

(5) Legal cannabis businesses support more than 428,000 jobs throughout the United States.

(6) Legal cannabis sales totaled $25,000,000,000 in 2021 and are projected to reach $45,000,000,000 by 2025.

(7) According to the American Civil Liberties Union (ACLU), enforcing cannabis prohibition laws costs taxpayers approximately $3,600,000,000 a year.

(8) The continued enforcement of cannabis prohibition laws resulted in over 350,000 arrests in 2020, disproportionately impacting people of color who are almost 4 times more likely to be arrested for cannabis possession than their White counterparts, despite equal rates of use across populations.

(9) People of color and Native Americans have been historically targeted by discriminatory sentencing practices resulting in Black men receiving drug sentences that are 13.1 percent longer than sentences imposed for White men and Latinos being nearly 6.5 times more likely to receive a Federal sentence for cannabis possession than non-Hispanic Whites.

(10) In 2013, simple cannabis possession was the fourth most common cause of deportation for any offense and the most common cause of deportation for drug law violations. Since 2003, the United States has deported more than 45,000 people whose most serious conviction was cannabis possession.

(11) Fewer than one-fifth of cannabis business owners identify as minorities and only approximately 2 percent are Black.

(12) Applicants for cannabis licenses are limited by numerous laws, regulations, and exorbitant permit applications, licensing fees, and costs in these States, which can require more than $700,000.

(13) Historically disproportionate arrest and conviction rates make it particularly difficult for people of color to enter the legal cannabis marketplace, as most States bar these individuals from participating.

(14) Federal law severely limits access to loans and capital for cannabis businesses, disproportionately impacting minority and Tribal small business owners.

(15) Some States, Indian Tribes, and municipalities have taken proactive steps to mitigate inequalities in the legal cannabis marketplace and ensure equal participation in the industry.

In this Act:

(1) CANNABIS; CANNABIS PRODUCT.—The terms “cannabis” and “cannabis product” have the same meanings given such terms in subsection (ss) of section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321) (as added by section 502 of this Act).

(2) CANNABIS OFFENSE.—The term “cannabis offense” means a criminal offense related to cannabis—

(A) that, under Federal law, is no longer punishable pursuant to this Act or the amendments made under this Act; or

(B) that, under State law, is no longer an offense or that was designated a lesser offense or for which the penalty was reduced under State law pursuant to or following the adoption of a State law authorizing the sale or use of cannabis.

(3) INDIAN TRIBE.—The term “Indian Tribe” means the governing body of any individually identified and federally recognized Indian or Alaska Native tribe, band, nation, pueblo, village, community, affiliated Tribal group, or component reservation included on the list published most recently as of the date of enactment of this Act pursuant to section 104(a) of the Federally Recognized Indian Tribe List Act of 1994 (25 U.S.C. 5131(a)).

(a) Cannabis removed from schedule of controlled substances.—

(1) REMOVAL IN STATUTE.—Schedule I of section 202 of the Controlled Substances Act (21 U.S.C. 812) is amended—

(A) in subsection (c)—

(i) by striking “(10) Marihuana.”; and

(ii) in paragraph (17), by inserting “in cannabis (as defined in section 201(ss)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(ss)(1))) or tetrahydrocannabinols” before “in hemp”; and

(B) in subsection (d)(2), by adding at the end the following new subparagraph:

“(C) Such term does not include any substance made of or derived from cannabis (as defined in section 201(ss)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(ss)(1)) or hemp (as defined in section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o))”.

(2) REMOVAL FROM SCHEDULE.—Not later than 180 days after the date of the enactment of this Act, the Attorney General shall finalize a rulemaking under section 201(a)(2) of the Controlled Substances Act (21 U.S.C. 811(a)(2)) removing marihuana and tetrahydrocannabinols in cannabis (as defined in section 201(ss)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(ss)(1))) from the schedules of controlled substances. For the purposes of the Controlled Substances Act, marihuana and tetrahydrocannabinols in cannabis (as so defined) shall each be deemed to be a drug or other substance that does not meet the requirements for inclusion in any schedule. A rulemaking under this paragraph shall be considered to have taken effect as of the date of enactment of this Act for purposes of any offense committed, case pending, conviction entered, and, in the case of a juvenile, any offense committed, case pending, and adjudication of juvenile delinquency entered before, on, or after the date of enactment of this Act.

(3) RESCHEDULING REVIEW OF NON-CANNABIS DERIVED TETRAHYDROCANNIBINOLS AND CANNABIMIMETIC AGENTS.—

(A) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Attorney General shall initiate a review of the schedules applicable to the substances described in subsections (c)(17) and (d) of Schedule I of section 202 of the Controlled Substances Act (21 U.S.C. 812).

(B) MOTION TO TRANSFER.—Pursuant to the findings of the review conducted under subparagraph (A), the Secretary of Health and Human Services shall, as appropriate, initiate a motion to transfer such substances between schedules pursuant to section 201 of the Controlled Substances Act (21 U.S.C. 811).

(b) Conforming amendments to controlled substances act.—The Controlled Substances Act (21 U.S.C. 801 et seq.) is amended—

(1) in section 102 (21 U.S.C. 802)—

(A) by striking paragraph (16); and

(B) in paragraph (44), by striking “marihuana,”;

(2) in section 401(b) (21 U.S.C. 841(b))—

(A) in paragraph (1)—

(i) in subparagraph (A)—

(I) in clause (vi), by inserting “or” after the semicolon;

(II) by striking clause (vii); and

(III) by redesignating clause (viii) as clause (vii);

(ii) in subparagraph (B)—

(I) in clause (vi), by inserting “or” after the semicolon;

(II) by striking clause (vii); and

(III) by redesignating clause (viii) as clause (vii);

(iii) in subparagraph (C), in the first sentence, by striking “subparagraphs (A), (B), and (D)” and inserting “subparagraphs (A) and (B)”;

(iv) by striking subparagraph (D);

(v) by redesignating subparagraph (E) as subparagraph (D); and

(vi) in subparagraph (D)(i), as so redesignated, by striking “subparagraphs (C) and (D)” and inserting “subparagraph (C)”;

(B) by striking paragraph (4); and

(C) by redesignating paragraphs (5), (6), and (7) as paragraphs (4), (5), and (6), respectively;

(3) in section 402(c)(2)(B) (21 U.S.C. 842(c)(2)(B)), by striking “, marihuana,”;

(4) in section 403(d)(1) (21 U.S.C. 843(d)(1)), by striking “, marihuana,”;

(5) in section 418(a) (21 U.S.C. 859(a)), by striking the last sentence;

(6) in section 419(a) (21 U.S.C. 860(a)), by striking the last sentence;

(7) in section 422(d) (21 U.S.C. 863(d))—

(A) in the matter preceding paragraph (1), by striking “marijuana, cocaine, hashish, hashish oil,” and inserting “cocaine,”; and

(B) in paragraph (5), by striking “, such as a marihuana cigarette,”;

(8) in section 516(d) (21 U.S.C. 886(d)), by striking “section 401(b)(6)” each place the term appears and inserting “section 401(b)(5)”; and

(9) in section 1010(b) (21 U.S.C. 960(b))—

(A) in paragraph (1)—

(i) in subparagraph (F), by inserting “or” after the semicolon;

(ii) by striking subparagraph (G);

(iii) by redesignating subparagraph (H) as subparagraph (G); and

(iv) in subparagraph (G), as so redesignated, by striking the period at the end and inserting a semicolon;

(B) in paragraph (2)—

(i) in subparagraph (F), by inserting “or” after the semicolon;

(ii) by striking subparagraph (G);

(iii) by redesignating subparagraph (H) as subparagraph (G); and

(iv) in subparagraph (G), as so redesignated, by striking the period at the end and inserting a semicolon;

(C) by striking paragraph (4); and

(D) by redesignating paragraphs (5), (6), and (7) as paragraphs (4), (5), and (6), respectively.

(c) Other conforming amendments.—

(1) NATIONAL FOREST SYSTEM DRUG CONTROL ACT OF 1986.—The National Forest System Drug Control Act of 1986 (16 U.S.C. 559b et seq.) is amended—

(A) in section 15002(a) (16 U.S.C. 559b(a)) by striking “marijuana and other”;

(B) in section 15003(2) (16 U.S.C. 559c(2)) by striking “marijuana and other”; and

(C) in section 15004(2) (16 U.S.C. 559d(2)) by striking “marijuana and other”.

(2) INTERCEPTION OF COMMUNICATIONS.—Section 2516 of title 18, United States Code, is amended—

(A) in subsection (1)(e), by striking “marihuana,”; and

(B) in subsection (2) by striking “marihuana”.

(3) FMCSA PROVISIONS.—

(A) CONFORMING AMENDMENT.—Section 31301(5) of title 49, United States Code, is amended by striking “section 31306,” and inserting “sections 31306, 31306a, and subsections (b) and (c) of section 31310,”.

(B) DEFINITION.—Section 31306(a) of title 49, United States Code, is amended—

(i) by striking “means any substance” and inserting the following: “means—

“(1) any substance”; and

(ii) by striking the period at the end and inserting “; and

“(2) any substance not covered under paragraph (1) that was a substance under such section as of December 1, 2018, and specified by the Secretary of Transportation.”.

(C) DISQUALIFICATIONS.—Section 31310(b) of title 49, United States Code, is amended by adding at the end the following:

“(3) In this subsection and subsection (c), the term ‘controlled substance’ has the meaning given such term in section 31306(a).”.

(4) FAA PROVISIONS.—Section 45101 of title 49, United States Code, is amended—

(A) by striking “means any substance” and inserting the following: “means—

“(A) any substance”; and

(B) by striking the period at the end and inserting “; and

“(B) any substance not covered under subparagraph (A) that was a substance under such section as of December 1, 2018, and specified by the Secretary of Transportation.”.

(5) FRA PROVISIONS.—Section 20140(a) of title 49, United States Code, is amended—

(A) by striking “means any substance” and inserting the following: “means—

“(1) any substance”; and

(B) by striking the period at the end and inserting “; and

“(2) any substance not covered under paragraph (1) that was a substance under such section as of December 1, 2018, and specified by the Secretary of Transportation.”.

(6) FTA PROVISIONS.—Section 5331(a)(1) of title 49, United States Code, is amended—

(A) by striking “means any substance” and inserting the following: “means—

“(A) any substance”; and

(B) by striking the period at the end and inserting “; and

“(B) any substance not covered under subparagraph (A) that was a substance under such section as of December 1, 2018, and whose use the Secretary of Transportation decides has a risk to transportation safety.”.

(7) PRISON CONTRABAND.—Section 1791(d)(1) of title 18, United States Code, is amended—

(A) in subparagraph (A), by striking “marijuana or”;

(B) in subparagraph (B), by striking “marijuana or”; and

(C) in subparagraph (D), by inserting “, cannabis, as defined in section 3 of the Cannabis Administration and Opportunity Act,” after “subsection)”.

(8) OTHER CONTRABAND.—Section 80302(a)(1) of title 49, United States Code, is amended by striking “, including marihuana (as defined in section 102 of that Act (21 U.S.C. 802)),”.

(9) TARIFF ACT PROVISIONS.—Section 584(a)(2) of the Tariff Act of 1930 (19 U.S.C. 1584(a)(2)) is amended—

(A) by striking the second sentence and inserting “If any of such merchandise so found consists of smoking opium or opium prepared for smoking, the master of such vessel or person in charge of such vehicle or the owner of such vessel or vehicle or any person directly or indirectly responsible for smoking opium or opium prepared for smoking being in such merchandise shall be liable to a penalty of $500 for each ounce thereof so found.”; and

(B) by striking the last sentence and inserting “As used in this paragraph, the term ‘opiate’ shall have the same meaning given that term by sections 102(18) of the Controlled Substances Act (21 U.S.C. 802(18)).”.

(d) Retroactivity.—

(1) IN GENERAL.—The amendments made by this section to the Controlled Substances Act (21 U.S.C. 801 et seq.) are retroactive and shall apply to any offense committed, case pending, conviction entered, and, in the case of a juvenile, any offense committed, case pending, or adjudication of juvenile delinquency entered before, on, or after the date of enactment of this Act.

(2) APPLICATION TO PENDING ACTIONS.—With respect to any pending criminal charges or case and conviction awaiting sentencing that is impacted by the amendments to the Controlled Substances Act (21 U.S.C. 801 et seq.) made by this section, the Government shall drop the relevant charges or seek dismissal of all pending charges not later than 30 days after the date of enactment of this Act. Any person held in pretrial detention and entitled to dismissal of relevant charges under this provision, and not detained for any other reason, shall be entitled to issuance of a writ under section 1361 or 2241 of title 28, United States Code, to effectuate immediate release.

(3) APPLICATION TO DEFENDANTS PREVIOUSLY SENTENCED.—Not later than 60 days after the date of enactment of this Act, the Director of the Bureau of Prisons, United States Marshals Service, or United States Parole Commission, as applicable, shall release from its control, and the sentencing court shall enter an order vacating the conviction and sentence for, any individual convicted or sentenced before the date of enactment of this Act for any Federal offense involving marijuana, marihuana (as defined in section 202(16) of the Controlled Substances Act (21 U.S.C. 812(16))), or tetrahydrocannabinols and is not serving a sentence for any conduct not covered by this Act or serving multiple sentences as provided in section 3584 of title 18, United States Code. Any person not so timely released and entitled to such release under this provision shall be entitled to issuance of a writ under section 1361 or 2241 of title 28, United States Code, to effectuate immediate release.

(4) CUMULATIVE SENTENCING RECONSIDERATION.—In the case of a defendant who, before the date of enactment of this Act, was convicted or sentenced for any Federal offense involving marijuana, marihuana, or tetrahydrocannabinols, and, after vacatur of that sentence, is also serving a sentence for any other crime not covered by this Act, or in the case of a defendant who was convicted or sentenced for any Federal offense the sentencing range for which was elevated based on a prior conviction for an offense involving marijuana, marihuana, or tetrahydrocannabinols, the sentencing court may, on motion of the defendant, the Director of the Bureau of Prisons, the Attorney General, or, on its own motion, impose a reduced sentence after considering the factors set forth in section 3553(a) of title 18, United States Code.

(e) Special rule for federal employee testing.—Section 503 of the Supplemental Appropriations Act, 1987 (5 U.S.C. 7301 note) is amended by adding at the end the following:

“(h) Cannabis.—

“(1) TESTING FOR CANNABIS.—

“(A) IN GENERAL.—For purposes of Executive Order 12564, cannabis shall not be treated as an illegal drug.

“(B) EXCEPTION FOR DRUG TESTING.—Notwithstanding subparagraph (A) or the Cannabis Administration and Opportunity Act and the amendments made thereby, the Secretary of Health and Human Services or the head of an agency may deem cannabis to be a schedule I controlled substance within the meaning of section 102(6) of the Controlled Substances Act (21 U.S.C. 802(6)), and unlawful to possess under title II or III of such Act, exclusively for the purpose of drug testing of any law enforcement officer (as defined in section 8331 of title 5, United States Code) or any Federal employee in a position that the head of an agency determines, in writing, to have significant involvement in national security or the protection of life, property, public health, or public safety, provided that either such employee is subject to this section, Executive Order 12564, or other applicable Federal laws and orders.

“(2) DEFINITION.—The term ‘cannabis’ has the meaning given the term in section 3 of the Cannabis Administration and Opportunity Act”..”.

(f) Special rule for certain regulations.—

(1) IN GENERAL.—The amendments made by this section may not be construed to abridge the authority of the Secretary of Transportation, or the Secretary of the department in which the Coast Guard is operating, to regulate and screen for the use of a controlled substance.

(2) CONTROLLED SUBSTANCE DEFINED.—In this subsection, the term “controlled substance” means—

(A) any substance covered under section 102 of the Controlled Substances Act (21 U.S.C. 802) on the day before the date of enactment of this Act; and

(B) any substance not covered under subparagraph (A) that was a substance covered under section 102 of the Controlled Substances Act (21 U.S.C. 802) on December 1, 2018, and specified by the Secretary of Transportation.

(a) Transfer of jurisdiction from the Drug Enforcement Administration to the Department of Health and Human Services and the Department of the Treasury.—The functions of the Attorney General, acting through the Administrator of the Drug Enforcement Administration relating to cannabis enforcement, shall hereafter be administered by—

(1) the Secretary of Health and Human Services, and

(2) the Secretary of the Treasury.

(b) Redesignation of Alcohol and Tobacco Tax and Trade Bureau as Alcohol, Tobacco, and Cannabis Tax and Trade Bureau.—

(1) REDESIGNATION.—Section 1111(d) of the Homeland Security Act of 2002 (6 U.S.C. 531(d)) is amended by striking “Tax and Trade Bureau” each place it appears and inserting “Alcohol, Tobacco, and Cannabis Tax and Trade Bureau”.

(2) REFERENCES.—Any reference to the Tax and Trade Bureau or the Alcohol and Tobacco Tax and Trade Bureau in any law, regulation, map, document, record, or other paper of the United States shall be deemed to be a reference to the Alcohol, Tobacco, and Cannabis Tax and Trade Bureau.

(c) Memorandum of Understanding.—

(1) IN GENERAL.—For purposes of carrying out the purposes of this Act, not later than 180 days after the date of enactment of this Act, the Secretary of the Treasury (acting through the Alcohol, Tobacco, and Cannabis Tax and Trade Bureau, as so redesignated under subsection (b)) and the Secretary of Health and Human Services (acting through the Commissioner of Food and Drugs) shall enter into memorandum of understanding regarding coordination of their respective responsibilities with regard to regulation of cannabis and cannabis products.

(2) COMPLIANCE BURDENS.—For purposes of establishing the memorandum of understanding described in paragraph (1), the Secretary of the Treasury and the Secretary of Health and Human Services shall include consideration of—

(A) any compliance burdens imposed on persons involved in the cannabis industry who are subject to regulation under this Act and the amendments made by this Act, and

(B) to the greatest extent practicable, reduction of any unnecessary administrative duplication with respect to such regulation.

(a) State statutes as operative on termination of transportation; original packages.—All cannabis transported into any State or territory of the United States or remaining therein for use, consumption, sale, or storage therein, shall, upon arrival in that State or territory, be subject to the operation and effect of the laws of that State or territory enacted in the exercise of its police powers, to the same extent and in the same manner as though the cannabis had been produced in that State or territory, and shall not be exempt therefrom by reason of being introduced therein in original packages or otherwise.

(b) Shipment into States for possession or sale in violation of State law.—The shipment or transportation, in any manner or by any means whatsoever, of cannabis from a State, territory, or district of the United States, or place noncontiguous to but subject to the jurisdiction thereof, into any other State, territory, or district of the United States, or place noncontiguous to but subject to the jurisdiction thereof, or from any foreign country into any State, territory, or district of the United States, or place noncontiguous to but subject to the jurisdiction thereof, which said cannabis is intended, by any person interested therein, to be received, possessed, sold, or in any manner used, either in the original package or otherwise, in violation of any law of that State, territory, or district of the United States, or place noncontiguous to but subject to the jurisdiction thereof, is prohibited.

(c) Transportation of cannabis and cannabis products.—No State or Indian Tribe may prohibit the transportation or shipment of cannabis or cannabis products through the State or the territory of the Indian Tribe, as applicable.

(d) Injunctive relief.—Section 2 of the Victims of Trafficking and Violence Protection Act of 2000 (27 U.S.C. 122a) is amended—

(1) in subsection (a)—

(A) by redesignating paragraphs (3) and (4) as paragraphs (4) and (5), respectively; and

(B) by inserting after paragraph (2) the following new paragraph:

“(3) the term ‘cannabis’ has the meaning given the term in section 3 of the Cannabis Administration and Opportunity Act;”; and

(2) in subsections (b) and (c), by inserting “or cannabis” after “intoxicating liquor” each place it appears.

(a) In general.—

(1) VIOLATIONS OF CANNABIS LAWS OR REGULATIONS; PENALTIES AND INJUNCTIONS.—

(A) DEFINITION.—In this paragraph, the term “common or contract carrier” means a carrier holding a certificate of convenience and necessity, a permit for contract carrier by motor vehicle, or other valid operating authority under subtitle IV of title 49, United States Code, or under equivalent operating authority from a regulatory agency of the United States or of any State.

(B) CANNABIS DIVERSION.—

(i) IN GENERAL.—Except as provided in clause (ii), it shall be unlawful to—

(I) knowingly grow, manufacture, ship, transport, receive, possess, sell, or distribute or purchase 10 pounds or more of cannabis without authorization under a State law or pursuant to a permit issued under section 301 of the Federal Alcohol Administration Act, as added by section 511 of this Act; or

(II) knowingly possess 10 pounds or more of cannabis that bears no evidence of the payment of applicable State or local cannabis taxes in the State or locality where the cannabis is found, if—

(aa) the State or local government requires a stamp, impression, or other indication to be placed on packages or other containers of cannabis to evidence payment of cannabis taxes; and

(bb) the cannabis is in the possession of any person other than a person holding a permit under section 301 of the Federal Alcohol Administration Act, as added by section 511 of this Act;

(III) knowingly grow, manufacture, ship, transport, receive, possess, sell, or distribute or purchase 20 pounds or more of cannabis without authorization under a State law or pursuant to a permit issued under section 301 of the Federal Alcohol Administration Act, as added by section 511 of this Act; or

(IV) knowingly possess 20 pounds or more of cannabis that bears no evidence of the payment of applicable State or local cannabis taxes in the State or locality where the cannabis is found, if—

(aa) the State or local government requires a stamp, impression, or other indication to be placed on packages or other containers of cannabis to evidence payment of cannabis taxes; and

(bb) the cannabis is in the possession of any person other than a person holding a permit under section 301 of the Federal Alcohol Administration Act, as added by section 511 of this Act.

(ii) EXCEPTIONS.—Clause (i) shall not apply to—

(I) a common or contract carrier transporting the cannabis involved under a proper bill of lading or freight bill which states the quantity, source, and destination of the cannabis;

(II) a person—

(aa) who is licensed or otherwise authorized by the State where the cannabis is found to account for and pay cannabis taxes imposed by such State; and

(bb) who has complied with the accounting and payment requirements relating to such license or authorization with respect to the cannabis involved;

(III) an officer, employee, or other agent of the United States, an Indian Tribe, or a State, or any department, agency, or instrumentality of the United States, an Indian Tribe, or a State (including any political subdivision of an Indian Tribe or a State) having possession of the cannabis in connection with the performance of official duties; or

(IV) a person—

(aa) involved in the manufacture, marketing, or distribution of a drug containing cannabis that is otherwise in compliance with State and Federal law; and

(bb) who possesses cannabis in connection with the lawful activities described in item (aa).

(iii) PENALTY.—Any person who violates—

(I) subclause (I) or (II) of clause (i) shall be imprisoned not more than 1 year, fined not more than $50,000, or both; or

(II) subclause (III) or (IV) of clause (i) shall be imprisoned not more than 5 years, fined not more than $100,000, or both.

(2) FINES.—The penalty provided for in this subsection may be recovered by the Secretary of the Treasury or by an action brought by the Attorney General in any court of competent jurisdiction.

(3) ENFORCEMENT.—It shall be the duty of the Attorney General upon the request of the Secretary of the Treasury to bring an action for an injunction against any person who violates, disobeys or disregards any term or provision of this subtitle or of any lawful notice, order or regulation pursuant thereto; provided, however, that the Secretary of the Treasury shall furnish the Attorney General with such material, evidentiary matter or proof as may be requested by the Attorney General for the prosecution of such an action.

(b) Tracking and tracing regulations.—

(1) ISSUANCE OF TRACKING AND TRACING REGULATIONS.—

(A) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Secretary of the Treasury (referred to in this section as the “Secretary”), acting through the Administrator of the Alcohol, Tobacco, and Cannabis Tax and Trade Bureau and in coordination with the Secretary of Health and Human Services, shall issue regulations relating to the tracking and tracing of cannabis products pursuant to paragraph (2).

(B) GOOD FAITH CONSULTATION WITH INDIAN TRIBES.—In issuing regulations under subparagraph (A), the Secretary, acting through the Administrator of the Alcohol, Tobacco, and Cannabis Tax and Trade Bureau and in coordination with the Secretary of Health and Human Services, shall conduct good faith, meaningful, and timely consultations with Indian Tribes.

(2) REGULATIONS CONCERNING RECORDKEEPING FOR TRACKING AND TRACING.—

(A) IN GENERAL.—The Secretary shall promulgate regulations regarding the establishment and maintenance of records by any person who manufactures, processes, transports, distributes, receives, packages, holds, exports, or imports cannabis products.

(B) INSPECTION.—In promulgating the regulations described in subparagraph (A), the Secretary shall consider which records are needed for inspection to monitor the movement of cannabis products from the point of production through distribution to retail outlets to assist in investigating potential illicit trade, smuggling, or counterfeiting of cannabis products.

(C) CODES.—The Secretary may require codes on the labels of cannabis products or other designs or devices for the purpose of tracking or tracing the cannabis product through the distribution system.

(D) SIZE OF BUSINESS.—The Secretary shall take into account the size of a business in promulgating regulations under this section.

(E) RECORDKEEPING BY RETAILERS.—The Secretary shall not require any retailer to maintain records relating to individual purchasers of cannabis products for personal consumption.

(3) RECORDS INSPECTION.—

(A) IN GENERAL.—If the Secretary has a reasonable belief that a cannabis product is part of an illicit trade or smuggling or is a counterfeit product, each person who manufactures, processes, transports, distributes, receives, holds, packages, exports, or imports cannabis products shall, at the request of an officer or employee duly designated by the Secretary, permit such officer or employee, at reasonable times and within reasonable limits and in a reasonable manner, upon the presentation of appropriate credentials and a written notice to such person, to have access to and copy all records (including financial records) relating to such article that are needed to assist the Secretary in investigating potential illicit trade, smuggling, or counterfeiting of cannabis products. The Secretary shall not authorize an officer or employee of the government of any of the several States to exercise authority under the preceding sentence on Indian country without the express written consent of the Indian Tribe involved.

(B) FAILURE TO COMPLY.—

(i) COMPEL INSPECTIONS.—The district courts of the United States shall have the authority, pursuant to a civil action brought by the Secretary, to compel access by any officer or employee duly designated by the Secretary to any relevant records described in subparagraph (A).

(ii) PENALTY.—Any person who—

(I) denies access to any relevant records described in subparagraph (A) to any officer or employee duly designated by the Secretary; or

(II) fails to comply with an order issued by a district court pursuant to clause (i),

shall be fined not more than $10,000.

(4) KNOWLEDGE OF ILLEGAL TRANSACTION.—

(A) NOTIFICATION.—If the manufacturer or distributor of a cannabis product has knowledge which reasonably supports the conclusion that a cannabis product manufactured or distributed by such manufacturer or distributor that has left the control of such person may be or has been—

(i) imported, exported, distributed, or offered for sale in interstate commerce by a person without paying duties or taxes required by Federal, Tribal, or State law; or

(ii) imported, exported, distributed, or diverted for possible illicit marketing,

the manufacturer or distributor shall promptly notify the Attorney General and the Secretary of such knowledge.

(B) KNOWLEDGE DEFINED.—For purposes of this paragraph, the term “knowledge” as applied to a manufacturer or distributor means—

(i) the actual knowledge that the manufacturer or distributor had; or

(ii) the knowledge which a reasonable person would have had under like circumstances or which would have been obtained upon the exercise of due care.

(5) CONSULTATION.—In carrying out this subsection, the Secretary shall consult with the Attorney General and the Commissioner of Food and Drugs, as appropriate.

(6) CONSIDERATION OF STATE AND OTHER PRECEDENT.—In promulgating the regulations described in this subsection, the Secretary shall consider—

(A) recommendations and findings by the Cannabis Products Advisory Committee established under section 1111 of the Federal Food, Drug, and Cosmetic Act;

(B) current practices of States regarding cannabis and the practices of other regulated industries; and

(C) whether, during the 3-year period described in section 505(b)(1), unique standards for cannabis specified for medical use under State law are necessary or appropriate.

(a) In general.—The Comptroller General of the United States shall conduct an evaluation of the societal impact of the legalization by States of adult-use of cannabis. Such evaluation shall address, where information and data are available, a review of the following:

(1) Federal and State law enforcement activities, including—

(A) arrests related to illicit use, possession, production, manufacture, and distribution of cannabis; and

(B) diversion and seizures of cannabis.

(2) Employment and the receipt of Federal welfare assistance.

(3) Changes in the utilization of health care, including hospitalization related to methamphetamine and narcotic use and the use of cannabis for medical purposes.

(4) Analysis of tax revenue remitted to States resulting from legal cannabis sales.

(5) Any additional areas identified by the Comptroller General of the United States.

(b) Report.—The Comptroller General of the United States—

(1) not later than 2 years after the date of enactment of this Act, shall brief the Committee on Finance, the Committee on Health, Education, Labor, and Pensions, and the Committee on the Judiciary of the Senate and the Committee on Ways and Means, the Committee on Energy and Commerce, and the Committee on the Judiciary of the House of Representatives on the preliminary findings of the evaluation under subsection (a); and

(2) at a date agreed upon at the time of the preliminary briefing described in paragraph (1), submit a final report to such committees.

(a) In general.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), in consultation with the Director of the National Institutes of Health, shall conduct or support research on the impacts of cannabis.

(b) Topics.—The research conducted or supported under subsection (a) may include research on—

(1) the effects of tetrahydrocannabinol on the human brain;

(2) the efficacy of cannabis as a treatment for specific diseases and conditions, including any impact on chronic pain and post-traumatic stress disorder;

(3) the impact of the use of cannabis on—

(A) pulmonary function;

(B) cardiovascular events;

(C) cancer, including testicular, ovarian, transitional cell, and head, neck, and oral cancers, and chronic illnesses;

(D) mania;

(E) psychosis;

(F) cognitive effects; and

(G) cannabinoid hyperemesis syndrome; and

(4) the identification of additional medical benefits, harms, and uses of cannabis.

(c) Considerations.—In conducting or supporting the research under subsection (a), the Secretary may consider—

(1) varying forms of cannabis, including—

(A) full plants and extracts; and

(B) different types of cannabis with significant variation in phenotypic traits and various ratios of tetrahydrocannabinol and cannabidiol in chemical composition; and

(2) varying methods of cannabis delivery, including combustible and non-combustible inhalation and ingestion.

(d) Annual reports.—Not later than 18 months after the date of enactment of this Act, and annually thereafter for the next 4 years, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, a report that includes an overview of the research conducted and supported under this section.

(e) Funding.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $200,000,000 for each of fiscal years 2023 through 2027 to carry out this section.

(a) In general.—Section 392A of the Public Health Service Act (42 U.S.C. 280b–1) is amended—

(1) in the section heading, by inserting “and adverse health effects of cannabis use” after “substances”;

(2) in subsection (a)—

(A) in paragraph (2)—

(i) in subparagraph (C) by inserting “and adverse health effects of cannabis use” before the period; and

(ii) in subparagraph (D) by inserting “, cannabis, and polysubstance use” before the period; and

(B) in paragraph (4), by inserting “and collect data to better understand the use and health effects of cannabis, stimulants, and polysubstances, and” after “conduct studies and evaluations”;

(3) in subsection (d), by striking “$496,000,000 for each of fiscal years 2019 through 2023” and inserting “$596,000,000 for each of fiscal years 2023 through 2027”; and

(4) by adding at the end the following:

“(e) Additional funding.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $100,000,000 for each of fiscal years 2023 through 2027 to carry out this section.”.

Part D of title V of the Public Health Service Act (42 U.S.C. 290dd et seq.) is amended by adding at the end the following:

(a) In general.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), in consultation with the Administrator of the National Highway Traffic Safety Administration, shall fund and oversee the production, broadcasting, and evaluation of a national public service media campaign to prevent and reduce underage cannabis use and cannabis impaired driving. Such campaign shall—

(1) educate the public about—

(A) the negative consequences of underage cannabis use and cannabis impaired driving; and

(B) the public health and safety benefits of evidence-based and evidence-informed policies to reduce underage cannabis use and cannabis impaired driving, and build community and parental support for, and cooperation with, enforcement of such policies; and

(2) be conducted—

(A) through multiple media sources;

(B) in a manner that is culturally and linguistically appropriate; and

(C) in a manner that reflects best practices in public health communication, including in accessible formats.

(3) CONSULTATION REQUIREMENT.—In carrying out the campaign under this subsection, the Secretary shall consult with interested parties, including medical, public health, consumer, parent, disability, law enforcement, community-based, and other stakeholders, as determined by the Secretary.

(b) Education and awareness campaign for cannabis use.—The Secretary, in coordination with the heads of other appropriate departments and agencies and working through existing programs and activities, as appropriate, shall advance the education and awareness of the public (including health care providers, consumers, workplaces, and other appropriate entities) regarding cannabis use. The education and awareness campaigns under this subsection shall address—

(1) any dangers and negative consequences of cannabis use;

(2) awareness and prevention of cannabis use disorder;

(3) the effects of cannabis on the human body, including with respect to the use of cannabis in different circumstances such as the workplace and while operating motor vehicles;

(4) the effects of cannabis when mixed with other substances; and

(5) other relevant public health or biomedical research, as the Secretary determines appropriate.

(c) Report to Congress.—The Secretary shall submit an annual report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives detailing the production, broadcasting, and evaluation of the campaigns under subsections (a) and (b). Such reports shall include—

(1) details regarding the effectiveness of such campaigns in reducing underage cannabis use;

(2) the need for, and likely effectiveness of, an expanded campaign under either such subsection; and

(3) details regarding the consultation the Secretary engaged in pursuant to subsection (a)(2).

(d) Funding.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $5,000,000 for each of fiscal years 2023 through 2027 to carry out this section.

(a) In general.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Director of the National Institutes of Health and in collaboration with the Commissioner of Food and Drugs and the Attorney General, shall take steps to increase the availability and diversity of research grade cannabis products for intramural and extramural research activities, including cannabis products with varied cannabinoid concentrations and cannabis products that reflect regional differences in products available to be sold directly to consumers.

(b) Guidance.—In carrying out subsection (a), the Secretary may develop guidance clarifying how entities engaged in extramural research supported by the Federal Government may access cannabis products available to be sold directly to consumers.

(c) Congressional briefing.—Not later than 1 year after the date of enactment of this Act, the Secretary shall brief the Committee on Health, Education, Labor, and Pensions and the Committee on the Judiciary of the Senate and the Committee on Energy and Commerce and the Committee on the Judiciary of the House of Representatives on the activities under subsection (a).

(d) Funding.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $275,000,000 for each of fiscal years 2023 through 2027 to carry out this section.

Part A of title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) is amended by inserting at the end the following:

(a) In general.—There is established within the Department of Health and Human Services a Cannabis Research Interagency Advisory Committee (referred to in this subsection as the “Advisory Committee”) for purposes of coordinating—

(1) Federal research activities relating to cannabis; and

(2) aspects of all Federal programs and activities relating to cannabis research, in order to ensure the adequacy and technical soundness of such programs and activities, to minimize barriers to such programs and activities, to provide for the full communication and exchange of information necessary to maintain adequate coordination of such programs and activities.

(b) Members.—The Advisory Committee established under subsection (a) shall consist of the heads of the following agencies or their designees:

(1) The National Institutes of Health.

(2) The Centers for Disease Control and Prevention.

(3) The Food and Drug Administration.

(4) The Substance Abuse and Mental Health Services Administration.

(5) The Office of the Assistant Secretary of Health.

(6) The Office of Minority Health.

(7) The Drug Enforcement Administration.

(8) The Alcohol, Tobacco, and Cannabis Tax and Trade Bureau (as so redesignated by section 102 of this Act).

(9) The Department of Transportation.

(10) Any other agency with subject matter expertise that the Secretary of Health and Human Services determines appropriate to advance research on cannabis.

(c) Responsibilities.—In carrying out its duties under this section, the Advisory Committee shall—

(1) monitor cannabis research across all relevant Federal departments and agencies, including coordination of Federal activities with respect to cannabis;

(2) develop a summary of advances in cannabis research;

(3) identify barriers to conducting or supporting cannabis research;

(4) make recommendations to the Secretary of Health and Human Services regarding any appropriate changes to such activities;

(5) make recommendations to the Secretary of Health and Human Services regarding public participation in decisions relating to cannabis research, and the process by which public feedback can be better integrated into such decisions;

(6) develop a strategic plan for the conduct of, and support for, cannabis research, which shall include—

(A) proposed budgetary requirements; and

(B) recommendations to ensure that cannabis research of the Department of Health and Human Services and of other Federal departments and agencies are not unnecessarily duplicative; and

(7) submit to Congress and the President—

(A) an annual update on the summary of advances described in paragraph (2); and

(B) an annual update to the strategic plan described in paragraph (5), including any progress made in achieving the goals outlined in such strategic plan.

(a) In general.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall award grants, contracts, or cooperative agreements to public and nonprofit entities (including consortiums of such entities) to conduct or support research on short- and long-term health effects of cannabis, considering beneficial and harmful effects and public health impacts. Such research may—

(1) consider the etiology, epidemiology, and health effects of cannabis use in at-risk or under researched populations, such as pediatric and older populations, individuals with chronic illnesses, pregnant and lactating women and their infants and children, and heavy cannabis users;

(2) consider the pharmacokinetic and pharmacodynamic properties of cannabis, modes of delivery, different concentrations, in various populations, including the dose-response relationships of cannabis and tetrahydrocannabinol or other cannabinoids;

(3) consider the harms and benefits associated with understudied cannabis products, such as edibles, concentrates, and topical products;

(4) consider the short- and long-term harms and benefits associated with exposure to chemicals and other products commonly involved in the growing, possessing, and selling of cannabis;

(5) utilize clinical trials on the potential beneficial and harmful health effects of using different forms of cannabis, such as inhaled whole cannabis plant and oral cannabis;

(6) seek to characterize the health effects of cannabis on unstudied and understudied health endpoints, such as epilepsy in pediatric populations, symptoms of posttraumatic stress disorder, childhood and adult cancers, cannabis-related overdoses and poisonings, and other high-priority health endpoints; and

(7) provide support for the development of novel diagnostic technologies that allow for rapid, accurate, and noninvasive assessment of cannabis exposure and impairment.

(b) Application.—To be eligible to receive an award under this section, an entity shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.

(c) Priority.—In selecting award recipients under this section, the Secretary shall give priority to any entity that is a minority-serving institution (defined, for purposes of this subsection, as an institution and program described in section 326(e)(1) of the Higher Education Act of 1965 (20 U.S.C. 1063b(e)(1)) and institution described in section 371(a) of such Act (20 U.S.C. 1067q(a))).

(d) Considerations.—In making awards under this section, the Secretary, to the extent practicable, may ensure equitable distribution of awards among the geographical regions of the United States.

(e) Reporting.—

(1) REPORTS FROM ENTITIES.—Each entity, or consortium of such entities, that receives an award under this section shall submit an annual report to the Secretary on the activities conducted under such award, and other information as the Secretary may require.

(2) REPORT TO CONGRESS.—Not later than 5 years after the date of enactment of this Act and every 5 years thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that provides a summary of the activities associated with awards made under this section.

(3) PUBLIC AVAILABILITY.—The Secretary shall make reports submitted under paragraph (2) publicly available on the website of the Department of Health and Human Services.

(f) Funding.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $200,000,000 for each of fiscal years 2023 through 2027 to carry out this section.

(a) Clinical trials required.—

(1) IN GENERAL.—The Secretary of Veterans Affairs shall carry out a series of clinical trials on the effects of medical-grade cannabis on the health outcomes of covered veterans diagnosed with chronic pain and covered veterans diagnosed with post-traumatic stress disorder.

(2) REQUIRED ELEMENTS.—The clinical trials required by paragraph (1) shall include—

(A) with respect to covered veterans diagnosed with chronic pain, an evaluation of the effects of the use of cannabis on—

(i) osteopathic pain (including pain intensity and pain-related outcomes);

(ii) the reduction or increase in opioid use or dosage;

(iii) the reduction or increase in benzodiazepine use or dosage;

(iv) the reduction or increase in alcohol use;

(v) inflammation;

(vi) sleep quality;

(vii) agitation; and

(viii) quality of life; and

(B) with respect to covered veterans diagnosed with post-traumatic stress disorder, an evaluation of the effects of the use of cannabis on—

(i) the symptoms of post-traumatic stress disorder (PTSD) as established by or derived from the clinician administered PTSD scale, the PTSD checklist, the PTSD symptom scale, the post-traumatic diagnostic scale, and other applicable methods of evaluating symptoms of post- traumatic stress disorder;

(ii) the reduction or increase in benzodiazepine use or dosage;

(iii) the reduction or increase in alcohol use;

(iv) mood;

(v) anxiety;

(vi) social functioning;

(vii) agitation;

(viii) suicidal ideation; and

(ix) sleep quality, including frequency of nightmares and night terrors.

(3) OPTIONAL ELEMENTS.—The clinical trials required by paragraph (1) may include an evaluation of the effects of the use of cannabis to treat chronic pain and post-traumatic stress disorder on—

(A) pulmonary function;

(B) cardiovascular events;

(C) head, neck, and oral cancer;

(D) testicular cancer;

(E) ovarian cancer;

(F) transitional cell cancer;

(G) intestinal inflammation;

(H) motor vehicle accidents;

(I) mania;

(J) psychosis;

(K) cognitive effects;

(L) cannabinoid hyperemesis syndrome;

(M) neuropathy;

(N) spasticity;

(O) substance use disorder; or

(P) mental health disorder.

(b) Long-Term observational study.—The Secretary may carry out a long-term observational study of the participants in the clinical trials required by subsection (a).

(c) Type of cannabis.—

(1) IN GENERAL.—In carrying out the clinical trials required by subsection (a), the Secretary shall study varying forms of cannabis, including whole plant raw material and extracts.

(2) PLANT CULTIVARS.—Of the varying forms of cannabis required under paragraph (1), the Secretary shall study not fewer than seven unique plant cultivars with ratios of tetrahydrocannabinol to cannabidiol in each of the following categories:

(A) Less than 1:5.

(B) Between 1:2 and 1:5.

(C) Approximately 1:2.

(D) Approximately 1:1.

(E) Approximately 2:1.

(F) Between 2:1 and 5:1.

(G) More than 5:1.

(d) Use of control and experimental groups.—The clinical trials required by subsection (a) shall include both a control group and an experimental group that shall—

(1) be of similar size and structure; and

(2) represent the demographics of the veteran population, as determined by the most recent data from the American Community Survey of the Bureau of the Census that is available prior to the commencement of the clinical trials.

(e) Limitation on enrollment of certain veterans.—In enrolling veterans in a clinical trial under subsection (a), the Secretary shall avoid enrolling veterans who—

(1) have existing substance use disorder or are at high-risk for developing substance use disorder; or

(2) have contraindications to medicinal cannabis, which may include—

(A) veterans with acute psychosis or at-risk of psychosis;

(B) veterans for whom cannabis is contraindicated based on current medications taken, prescribed and nonprescribed;

(C) veterans with severe cardiovascular, immunological, liver, or kidney disease; and

(D) veterans who are pregnant or breastfeeding.

(f) Data preservation.—The clinical trials required by subsection (a) shall include a mechanism to ensure the preservation of all data, including all data sets, collected or used for purposes of such trials in a manner that will facilitate further research.

(g) Implementation.—Not later than 180 days after the date of the enactment of this Act, the Secretary shall—

(1) develop a plan to implement this section and submit such plan to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives; and

(2) issue any requests for proposals the Secretary determines appropriate for such implementation.

(h) Effect on other benefits.—The eligibility or entitlement of a covered veteran to any other benefit under the laws administered by the Secretary or any other provision of law shall not be affected by the participation of the covered veteran in a clinical trial under subsection (a) or a study under subsection (b).

(i) Periodic reports.—During the five-year period beginning on the date of the enactment of this Act, the Secretary shall submit periodically, but not less frequently than annually, to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives reports on the implementation of this section.

(j) Covered veteran defined.—In this section, the term “covered veteran” means a veteran who is enrolled in the patient enrollment system of the Department of Veterans Affairs established and operated under section 1705(a) of title 38, United States Code.

Title VIII of the Higher Education Act of 1965 (20 U.S.C. 1161a et seq.) is amended by adding at the end the following:

In this subtitle:

(1) ADMINISTRATOR.—The term “Administrator” means the Administrator of the National Highway Traffic Safety Administration.

(2) SECRETARY.—The term “Secretary” means the Secretary of Transportation.

(3) THC.—The term “THC” means tetrahydrocannabinol.

(a) Cannabis-Impaired driving data.—

(1) IN GENERAL.—The Secretary shall collect and, as appropriate, share with the Secretary of Health and Human Services, data relating to cannabis-impaired driving, or a combination of cannabis and another substance, including through the collection of crash data specific to crashes involving drivers with—

(A) THC in their system; or

(B) a combination of THC and another substance in their system.

(2) NATIONAL ROADSIDE SURVEY.—

(A) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Administrator shall initiate a National Roadside Survey to collect data on drivers with THC in their system.

(B) REPORT.—Not later than 3 years after the date of enactment of this Act, the Secretary shall submit to the Committees on Commerce, Science, and Transportation, Environment and Public Works, and Health, Education, Labor, and Pensions of the Senate and the Committee on Transportation and Infrastructure of the House of Representatives a report summarizing the data acquired, and conclusions drawn, from the National Roadside Survey required under subparagraph (A).

(b) Research on risks of cannabis-Impaired driving.—

(1) STUDY REQUIRED.—

(A) IN GENERAL.—Not later than 3 years after the date of enactment of this Act, the Secretary shall carry out a study to evaluate and quantify the risks of cannabis-impaired driving.

(B) REQUIREMENTS.—The study required under subparagraph (A) shall analyze—

(i) whether there is an increased likelihood of crashing a motor vehicle after recent cannabis use;

(ii) the effect of cannabis on driving behavior;

(iii) whether there is a correlation between THC level (as tested in oral fluids) and level of impairment;

(iv) whether the current Standard Field Sobriety Test developed by the National Highway Traffic Safety Administration accurately identifies cannabis impairment;

(v) whether driving behavior changes depending on frequency of cannabis use;

(vi) whether there are any potential increased risks associated with using cannabis together with another substance; and

(vii) any other data necessary to improve safe driving outcomes, as determined by the Secretary.

(2) REPORT.—Not later than 3 years after the date of enactment of this Act, and annually thereafter until the date on which the study required under paragraph (1) is complete, the Secretary shall submit to the Committees on Commerce, Science, and Transportation, Environment and Public Works, and Health, Education, Labor, and Pensions of the Senate and the Committee on Transportation and Infrastructure of the House of Representatives a report summarizing the data acquired, and conclusions drawn, from the study required under paragraph (1).

(a) In general.—The Secretary shall research and implement data-driven strategies to educate the public about the dangers of cannabis-impaired driving, which shall include the following:

(1) CANNABIS-IMPAIRED DRIVING USE PREVENTION BEST PRACTICES.—

(A) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Secretary shall develop and issue best practices for States and communities to prevent cannabis-impaired driving, including impaired driving involving the use of cannabis and another substance and practices targeting drivers under the age of 21, in consultation with the Director of the Centers for Disease Control and Prevention, the Secretary of Health and Human Services, and the heads of other Federal agencies as appropriate.

(B) UPDATES.—Not less frequently than biannually, the Secretary shall update and reissue the best practices required under subparagraph (A) as new research and data becomes available.

(2) CANNABIS-IMPAIRED DRIVING USE PREVENTION CAMPAIGNS.—Not later than 2 years after the date of enactment of this Act, the Secretary shall establish and carry out national campaigns to prevent cannabis-impaired driving, including—

(A) cannabis-impaired driving involving the use of cannabis and another substance; and

(B) cannabis-impaired driving among drivers under the age of 21.

(b) Campaign evaluation.—Not less frequently than once every 3 years, the Secretary shall evaluate the effectiveness of the campaigns required under subsection (a)(2) and the activities carried out by States using a grant awarded under section 409 of title 23, United States Code, by using a variety of factors, including—

(1) collecting data, including behavioral data, and comparing that data from before and after the campaigns;

(2) (A) engaging with stakeholders that were involved in the campaigns; and

(B) analyzing feedback from those stakeholders on what the stakeholders saw as strengths and weaknesses of the campaigns;

(3) determining whether the campaigns accomplished the objectives the Secretary set out to accomplish through analysis of data relating to the campaigns; and

(4) any other factors the Secretary determines appropriate included in the document of the National Highway Traffic Safety Administration entitled “The Art of Appropriate Evaluation: A Guide for Highway Safety Program Managers” and dated December 2008 (or a successor document).

(c) Report.—Not later than 6 months after the date on which the Secretary completes an evaluation conducted under subsection (b), the Secretary shall submit to the Committees on Commerce, Science, and Transportation, Environment and Public Works, and Health, Education, Labor, and Pensions of the Senate and the Committee on Transportation and Infrastructure of the House of Representatives a report that—

(1) summarizes the data collected and provides the analysis of the data from an evaluation conducted under subsection (b);

(2) includes recommendations for future impaired driving campaigns; and

(3) includes any determinations that a national campaign or an activity carried out by a State using a grant awarded under section 409 of title 23, United States Code, is ineffective at preventing cannabis-impaired driving.

(a) In general.—Chapter 4 of title 23, United States Code, is amended by inserting after section 408 the following:

(b) Clerical amendment.—The analysis for chapter 4 of title 23, United States Code, is amended by inserting after the item relating to section 408 the following:

“409. State cannabis-impaired driving prevention grant program.”.

(a) In general.—Not later than 3 years after the date of enactment of this Act, and once every 2 years thereafter, the Secretary shall make a determination as to whether or not it is feasible to establish a national standard for determining impairment for cannabis-impaired driving.

(b) Rulemaking required.—If the Secretary determines that establishing a national standard relating to cannabis-impaired driving under subsection (a) is feasible, the Secretary shall, not later than 1 year after that determination, promulgate regulations establishing a model marijuana impairment standard for States.

In addition to amounts otherwise available, there is appropriated, out of any money in the Treasury not otherwise appropriated, $30,000,000 for each of fiscal years 2023 through 2027 to carry out sections 222 and 223.

(a) Cannabis justice office; community reinvestment grant program.—

(1) CANNABIS JUSTICE OFFICE.—Part A of title I of the Omnibus Crime Control and Safe Streets Act of 1968 (34 U.S.C. 10101 et seq.) is amended by inserting after section 109 the following:

(2) COMMUNITY REINVESTMENT GRANT PROGRAM.—Title I of the Omnibus Crime Control and Safe Streets Act of 1968 (34 U.S.C. 10101 et seq.) is amended by adding at the end the following:

(b) Cannabis opportunity program; equitable licensing grant program.—

(1) DEFINITIONS.—In this subsection:

(A) ADMINISTRATION; ADMINISTRATOR.—The terms “Administration” and “Administrator” mean the Small Business Administration and the Administrator thereof, respectively.

(B) ELIGIBLE INDIAN TRIBE.—The term “eligible Indian Tribe” means an Indian Tribe that has taken steps—

(i) to create an automatic process, at no cost to an individual, to expunge, destroy, or seal criminal records for cannabis offenses; and

(ii) to eliminate violations or other penalties for individuals under parole, probation, pre-trial, or other Tribal criminal supervision for a cannabis offense.

(C) ELIGIBLE STATE OR LOCALITY.—The term “eligible State or locality” means a State or locality that has taken steps—

(i) to create an automatic process, at no cost to an individual, to expunge, destroy, or seal criminal records for cannabis offenses; and

(ii) to eliminate violations or other penalties for individuals under parole, probation, pre-trial, or other State or local criminal supervision for a cannabis offense.

(D) FEDERAL POVERTY LEVEL.—The term “Federal Poverty Level” has the meaning given the term “poverty line” in section 2110(c) of the Social Security Act (42 U.S.C. 1397jj(c)).

(E) INDIVIDUAL ADVERSELY IMPACTED BY THE WAR ON DRUGS.—The term “individual adversely impacted by the War on Drugs” means an individual—

(i) who has had an income below 250 percent of the Federal Poverty Level for not fewer than 5 of the past 10 years, as of the date on which the individual seeks to participate in a program established under this section or an amendment made by this section; and

(ii) (I) who has been arrested for, or convicted of, the sale, possession, use, manufacture, or cultivation of cannabis (except for a conviction involving distribution to a minor); or

(II) the parent, sibling, spouse, or child of whom has been arrested for, or convicted of, an offense described in subclause (I).

(F) SMALL BUSINESS CONCERN OWNED AND CONTROLLED BY SOCIALLY AND ECONOMICALLY DISADVANTAGED INDIVIDUALS.—The term “small business concern owned and controlled by socially and economically disadvantaged individuals” has the meaning given the term in section 8(d)(3)(C) of the Small Business Act (15 U.S.C. 637(d)(3)(C)).

(G) STATE.—The term “State” means—

(i) each of the several States;

(ii) the District of Columbia;

(iii) the Commonwealth of Puerto Rico; and

(iv) any territory or possession of the United States.

(2) CANNABIS RESTORATIVE OPPORTUNITY PROGRAM.—

(A) IN GENERAL.—The Administrator shall establish and carry out a program, to be known as the “Cannabis Restorative Opportunity Program”, to provide loans and technical assistance under section 7(m) of the Small Business Act (15 U.S.C. 636(m)) to assist small business concerns owned and controlled by socially and economically disadvantaged individuals that operate—

(i) in eligible States or localities; or

(ii) in the jurisdiction of eligible Indian Tribes.

(B) TRIBAL SET ASIDE.—Of the amounts made available to carry out subparagraph (A), 5 percent shall be used to provide loans and technical assistance under section 7(m) of the Small Business Act (15 U.S.C. 636(m)) to assist small business concerns owned and controlled by socially and economically disadvantaged individuals that operate in the jurisdiction of an eligible Indian Tribe.

(3) EQUITABLE LICENSING GRANT PROGRAM.—The Administrator shall establish and carry out a grant program, to be known as the “Equitable Licensing Grant Program”, to provide any eligible State or locality or eligible Indian Tribe funds to develop and implement equitable cannabis licensing programs that minimize barriers to cannabis licensing and employment for individuals adversely impacted by the War on Drugs, provided that each grantee includes in the cannabis licensing program of the grantee not less than 4 of the following elements:

(A) A waiver of cannabis license application fees for an individual who—

(i) has had an income below 250 percent of the Federal Poverty Level for not fewer than 5 of the 10 years preceding the date on which the individual submits an application; and

(ii) is a first-time applicant.

(B) A prohibition on the denial of a cannabis license based on a conviction for a cannabis offense that took place before the eligible State or locality (or, in the case of a locality, the State in which the locality is located) or eligible Indian Tribe legalized the production, distribution, or possession of cannabis or the date of enactment of this Act, as applicable.

(C) A prohibition on restrictions for licensing relating to criminal convictions except with respect to a criminal conviction related to owning and operating a business.

(D) A prohibition on cannabis license holders engaging in suspicionless cannabis drug testing of their prospective or current employees, except with respect to drug testing for safety-sensitive positions under part 40 of title 49, Code of Federal Regulations, or any successor regulations.

(E) The establishment of a cannabis licensing board that—

(i) is reflective of the racial, ethnic, economic, and gender composition of the eligible State or locality or eligible Indian Tribe;

(ii) includes at least 1 representative from an eligible Indian Tribe that has jurisdiction within that eligible State or locality or that has Tribal jurisdiction, as applicable; and

(iii) shall serve as an oversight body of the equitable licensing program.

(4) STUDY ON PROGRAMS.—

(A) GAO STUDY.—Not later than 1 year after the date of enactment of this Act, and annually thereafter, the Comptroller General of the United States, in consultation with the Administrator, shall conduct a study on the individuals and entities receiving assistance under the Cannabis Restorative Opportunity and Equitable Licensing Programs established under paragraphs (2) and (3), respectively, which shall include—

(i) the types of assistance by State; and

(ii) a description of—

(I) the efforts by the Administration to increase access to capital for cannabis-related small business concerns owned and controlled by socially and economically disadvantaged individuals and small business concerns owned and controlled by individuals adversely impacted by the War on Drugs; and

(II) the racial, ethnic, economic and gender composition of the eligible State or locality.

(B) REPORT.—The Comptroller General of the United States shall submit a report on the results of each study conducted under subparagraph (A) to—

(i) the Committee on Small Business and Entrepreneurship of the Senate;

(ii) the Committee on Small Business of the House of Representatives;

(iii) the Committee on the Judiciary of the Senate; and

(iv) the Committee on the Judiciary of the House of Representatives.

(c) Appropriations.—

(1) COMMUNITY REINVESTMENT GRANT PROGRAM.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $1,650,000,000 for fiscal year 2023, to remain available until September 30, 2027, to carry out the program under part PP of title I of the Omnibus Crime Control and Safe Streets Act of 1968 (34 U.S.C. 10101 et seq.), as added by subsection (a)(2).

(2) CANNABIS RESTORATIVE OPPORTUNITY PROGRAM.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $17,000,000 for fiscal year 2023, to remain available until September 30, 2027, to carry out the program under subsection (b)(2).

(3) EQUITABLE LICENSING GRANT PROGRAM.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $550,000,000 for fiscal year 2023, to remain available until September 30, 2027, to carry out the program under subsection (b)(3).

(a) In general.—Part LL of title I of the Omnibus Crime Control and Safe Streets Act of 1968 (34 U.S.C. 10701 et seq.) is amended—

(1) in the part heading, by striking “opioid abuse grant” and inserting “opioid, stimulant, and substance use disorder”;

(2) in section 3021(a) (34 U.S.C. 10701(a))—

(A) in paragraph (2), by striking “opioid abuse” and inserting “substance use disorder”;

(B) in paragraph (7), by striking “opioid abuse” and inserting “substance use disorder”; and

(C) in paragraph (10), by striking “opioid” and inserting “substance misuse and”; and

(3) in section 3022(4) (34 U.S.C. 10702(4)), by striking “opioid abuse” and inserting “substance misuse and abuse”.

(b) Appropriation.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $200,000,000 for each of fiscal years 2023 through 2027 to carry out the program under part LL of title I of the Omnibus Crime Control and Safe Streets Act of 1968, as amended by subsection (a) of this section.

(a) Definitions relating to cannabis-Related legitimate businesses and service providers.—Section 3 of the Small Business Act (15 U.S.C. 632) is amended by adding at the end the following:

“(gg) Cannabis-Related legitimate businesses and service providers.—In this Act:

“(1) CANNABIS; CANNABIS PRODUCT.—The terms ‘cannabis’ and ‘cannabis product’ have the meanings given those terms in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321).

“(2) CANNABIS-RELATED LEGITIMATE BUSINESS.—The term ‘cannabis-related legitimate business’ means a manufacturer, producer, or any person or company that is a small business concern and that—

“(A) engages in any activity described in subparagraph (B) pursuant to a law established by an Indian tribe (as defined in section 8(a)(13)), a State, or a political subdivision of a State, as determined by that Indian tribe (as so defined), State, or political subdivision; and

“(B) participates in any business or organized activity that involves handling cannabis or cannabis products, including cultivating, producing, manufacturing, selling, transporting, displaying, dispensing, distributing, or purchasing cannabis or cannabis products.

“(3) CANNABIS-RELATED SERVICE PROVIDER.—The term ‘cannabis-related service provider’—

“(A) means a business, organization, or other person that—

“(i) sells goods or services to a cannabis-related legitimate business; or

“(ii) provides any business services, including the sale or lease of real or any other property, legal or other licensed services, or any other ancillary service, relating to cannabis; and

“(B) does not include a business, organization, or other person that participates in any business or organized activity that involves handling cannabis or cannabis products, including cultivating, producing, manufacturing, selling, transporting, displaying, dispensing, distributing, or purchasing cannabis or cannabis products.”.

(b) Small business development centers.—Section 21(c) of the Small Business Act (15 U.S.C. 648(c)) is amended by adding at the end the following:

“(9) Services for cannabis-Related legitimate businesses and service providers.—A small business development center may not decline to provide services to an otherwise eligible small business concern under this section solely because the concern is a cannabis-related legitimate business or cannabis-related service provider.”.

(c) Women’s business centers.—Section 29 of the Small Business Act (15 U.S.C. 656) is amended by adding at the end the following:

“(p) Services for cannabis-Related legitimate businesses and service providers.—A women’s business center may not decline to provide services to an otherwise eligible small business concern under this section solely because the concern is a cannabis-related legitimate business or cannabis-related service provider.”.

(d) Score.—Section 8(b)(1)(B) of the Small Business Act (15 U.S.C. 637(b)(1)(B)) is amended by adding at the end the following: “The head of the SCORE program established under this subparagraph may not decline to provide services to an otherwise eligible small business concern solely because the concern is a cannabis-related legitimate business or cannabis-related service provider.”.

(e) Veteran business outreach centers.—Section 32 of the Small Business Act (15 U.S.C. 657b) is amended by adding at the end the following:

“(h) Services for cannabis-Related legitimate businesses and service providers.—A Veteran Business Outreach Center may not decline to provide services to an otherwise eligible small business concern under this section solely because the concern is a cannabis-related legitimate business or cannabis-related service provider.”.

(f) Community Navigators Pilot Program.—Section 5004 of the American Rescue Plan Act (Public Law 117–2; 135 Stat. 90) is amended by adding at the end the following:

“(e) Assistance to cannabis-Related legitimate businesses and service providers.—The Administrator may not decline to make a grant to or enter into a contract or cooperative agreement with an entity under this section solely because the entity is a cannabis-related business or cannabis-related service provider (as defined in section 3 of the Small Business Act (15 U.S.C. 632)).”.

(g) 7(a) loans.—Section 7(a) of the Small Business Act (15 U.S.C. 636(a)) is amended by adding at the end the following:

“(38) LOANS TO CANNABIS-RELATED LEGITIMATE BUSINESSES AND SERVICE PROVIDERS.—The Administrator may not decline to provide a guarantee for a loan under this subsection, and a lender may not decline to make a loan under this subsection, to an otherwise eligible small business concern solely because the concern is a cannabis-related legitimate business or cannabis-related service provider.”.

(h) Disaster loans.—Section 7(b) of the Small Business Act (15 U.S.C. 636(b)) is amended by inserting after paragraph (15) the following:

“(16) ASSISTANCE TO CANNABIS-RELATED LEGITIMATE BUSINESSES AND SERVICE PROVIDERS.—The Administrator may not decline to provide assistance under this subsection to an otherwise eligible small business concern solely because the concern is a cannabis-related legitimate business or cannabis-related service provider.”.

(i) Microloans.—Section 7(m) of the Small Business Act (15 U.S.C. 636(m)) is amended by adding at the end the following:

“(14) ASSISTANCE TO CANNABIS-RELATED LEGITIMATE BUSINESSES AND SERVICE PROVIDERS.—The Administrator may not decline to make a loan or a grant under this subsection, and an eligible intermediary may not decline to provide assistance under this subsection to an otherwise eligible borrower, eligible intermediary, or eligible nonprofit entity (as applicable) solely because such borrower, intermediary, or nonprofit entity is a cannabis-related legitimate business or cannabis-related service provider.”.

(j) Small business investment company debentures To finance cannabis-Related legitimate businesses and service providers.—Part A of title III of the Small Business Investment Act of 1958 (15 U.S.C. 681 et seq.) is amended by adding at the end the following:

(k) State or local development company loans.—Title V of the Small Business Investment Act of 1958 (15 U.S.C. 695 et seq.) is amended by adding at the end the following:

(a) In general.—The Bureau of Labor Statistics shall regularly compile, maintain, and make public data on the demographics of—

(1) individuals who are business owners in the cannabis industry; and

(2) individuals who are employed in the cannabis industry.

(b) Demographic data.—The data collected under subsection (a) shall include data regarding—

(1) age;

(2) certifications and licenses;

(3) disability status;

(4) educational attainment;

(5) family and marital status;

(6) nativity;

(7) race and Hispanic ethnicity;

(8) school enrollment;

(9) veteran status; and

(10) sex.

(c) Confidentiality.—Notwithstanding any other provision in this section, the name, address, and other identifying information of an individual described in subsection (a) shall be kept confidential by the Bureau of Labor Statistics and not be made available to the public.

(d) Definitions.—In this section:

(1) CANNABIS.—The term “cannabis” has the meaning given such term in section 3.

(2) CANNABIS INDUSTRY.—The term “cannabis industry” means the industry, in any State, jurisdiction of an Indian Tribe, or locality in the United States, in which an individual or entity—

(A) conducts businesses pursuant to a permit issued under section 302 of the Federal Alcohol Administration Act, as added by section 511; or

(B) is otherwise licensed or permitted under the law in such State, jurisdiction of such Indian Tribe, or law in such locality to engage in a commercial cannabis-related activity.

(3) OWNER.—The term “owner”, with respect to a business, means an individual or entity that is defined as an owner under the State, Tribal, or local law where the individual or entity is licensed or permitted to operate such business.

(4) STATE.—The term “State” means—

(A) each of the several States;

(B) the District of Columbia;

(C) the Commonwealth of Puerto Rico; and

(D) any territory or possession of the United States.

Section 7 of the Small Business Act (15 U.S.C. 636) is amended by adding at the end the following:

“(o) Pilot program.—

“(1) DEFINITIONS.—In this subsection:

“(A) ELIGIBLE INTERMEDIARY.—The term ‘eligible intermediary’ means—

“(i) a private, nonprofit entity, including a private, nonprofit community development corporation, a consortium of private, nonprofit organizations or nonprofit community development corporations, and an agency of or nonprofit entity established by a Native American Tribal Government, that—

“(I) seeks or has been awarded a loan from the Administrator to make loans to small business concerns under this subsection; and

“(II) has not less than 1 year of experience making loans to startup or socially and economically disadvantaged small business concerns;

“(ii) a community development financial institution, as defined in section 103 of the Community Development Banking and Financial Institutions Act of 1994 (12 U.S.C. 4702); and

“(iii) a minority depository institution, as defined in section 308 of the Financial Institutions Reform, Recovery, and Enforcement Act of 1989 (12 U.S.C. 1463 note).

“(B) INDIVIDUAL ADVERSELY IMPACTED BY THE WAR ON DRUGS.—The term ‘individual adversely impacted by the War on Drugs’ has the meaning given the term in section 301(b) of the Cannabis Administration and Opportunity Act.

“(C) PROGRAM.—The term ‘Program’ means the small business intermediary lending pilot program established under paragraph (2).

“(D) SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERN.—The term ‘socially and economically disadvantaged small business concern’ has the meaning given the term in section 8(a)(4)(A).

“(2) ESTABLISHMENT.—There is established a 10-year small business intermediary lending pilot program under which the Administrator may—

“(A) make direct loans to eligible intermediaries for the purpose of making loans to startup small business concerns, small business concerns owned and controlled by individuals adversely impacted by the War on Drugs, or socially and economically disadvantaged small business concerns; and

“(B) in conjunction with the direct loans described in subparagraph (A), make grants to eligible intermediaries for the purpose of providing intensive marketing, management, regulatory compliance, and technical assistance to the small business concerns described in subparagraph (A) that receive a loan under this subsection.

“(3) LOANS TO ELIGIBLE INTERMEDIARIES.—

“(A) APPLICATION.—Each eligible intermediary desiring a loan under this subsection shall submit an application to the Administrator that describes—

“(i) the type of small business concerns to be assisted;

“(ii) the size and range of loans to be made;

“(iii) the interest rate and terms of loans to be made;

“(iv) the geographic area to be served and the economic, poverty, and unemployment characteristics of the area;

“(v) the status of small business concerns in the area to be served and an analysis of the availability of credit;

“(vi) the marketing, management, regulatory compliance, and other technical assistance to be provided in connection with a loan made under this subsection; and

“(vii) the qualifications of the applicant to carry out this subsection.

“(B) LOAN LIMITS.—No loan may be made to an eligible intermediary under this subsection if the total amount outstanding and committed to the eligible intermediary by the Administrator would, as a result of such loan, exceed $10,000,000 during the participation of the eligible intermediary in the Program.

“(C) LOAN DURATION.—Loans made by the Administrator under this subsection shall be for a term of 20 years.

“(D) APPLICABLE INTEREST RATE.—Loans made by the Administrator to an eligible intermediary under the Program shall bear an annual interest rate equal to the interest rate described in subsection (m)(3)(F)(ii).

“(E) FEES; COLLATERAL.—The Administrator may not charge any fees or require collateral with respect to any loan made to an eligible intermediary under this subsection.

“(F) DELAYED PAYMENTS.—The Administrator shall not require the repayment of principal or interest on a loan made to an eligible intermediary under the Program during the 2-year period beginning on the date of the initial disbursement of funds under that loan.

“(G) MAXIMUM PARTICIPANTS AND AMOUNTS.—During each fiscal years, the Administrator may make loans under the Program—

“(i) to not more than 30 eligible intermediaries; and

“(ii) in a total amount of not more than $300,000,000.

“(4) LOANS TO SMALL BUSINESS CONCERNS.—

“(A) IN GENERAL.—The Administrator, through an eligible intermediary, shall make loans to the small business concerns described in paragraph (2) for eligible uses under subsection (a).

“(B) MAXIMUM LOAN.—An eligible intermediary may not make a loan under this subsection of more than $200,000 to any 1 small business concern.

“(C) APPLICABLE INTEREST RATES.—

“(i) IN GENERAL.—Subject to clause (ii), a loan made by an eligible intermediary to a small business concern under this subsection—

“(I) may have a fixed or a variable interest rate; and

“(II) shall bear an interest rate specified by the eligible intermediary in the application of the eligible intermediary for a loan under this subsection.

“(ii) RESTRICTIONS.—The Administrator may limit the interest rate or provide forbearance or deferment on repayment of a loan made by an eligible intermediary to a small business concern under this section.

“(D) REVIEW RESTRICTIONS.—The Administrator may not review individual loans made by an eligible intermediary to a small business concern before approval of the loan by the eligible intermediary.

“(5) FUNDING.—In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, for fiscal year 2023, to remain available until September 30, 2027—

“(A) $90,000,000 to carry out paragraph (2)(A); and

“(B) $41,000,000 to carry out paragraph (2)(B).

“(6) TERMINATION.—The authority of the Administrator to make loans under the Program shall terminate on the date that is 10 years after the date of enactment of this subsection.

“(7) SENSE OF THE SENATE.—It is the sense of the Senate that the Administrator should issue regulations to ensure that the processing and disbursement of loans under this subsection prioritizes individuals adversely impacted by the War on Drugs.”.

(a) Definitions.—In this section—

(1) the terms “cannabis-related legitimate business” and “cannabis-related service provider” have the meanings given those terms in section 3 of the Small Business Act (15 U.S.C. 632), as added by section 303; and

(2) the term “individual adversely impacted by the War on Drugs” has the meaning given the term in section 301(b).

(b) Review.—The Administrator of the Small Business Administration—

(1) shall review regulations, policies, and guidance of the Administration to eliminate disparities for cannabis-related legitimate businesses and cannabis-related service providers, including by reducing regulatory burdens and increasing loan eligibility for minority businesses and individuals adversely impacted by the War on Drugs; and

(2) in carrying out paragraph (1), may consider effective, State-level systems designed to eliminate disparities for cannabis-related legitimate businesses and cannabis-related service providers.

(a) Expungement of federal cannabis offense convictions for individuals not under a criminal justice sentence.—

(1) IN GENERAL.—Not later than 1 year after the date of the enactment of this Act, each Federal district shall conduct a comprehensive review and issue an order expunging each conviction or adjudication of juvenile delinquency for a Federal cannabis offense entered by each Federal court in the district before the date of enactment of this Act and on or after May 1, 1971. Each Federal court shall also issue an order expunging any arrests associated with each expunged conviction or adjudication of juvenile delinquency.

(2) NOTIFICATION.—To the extent practicable, each Federal district shall notify each individual whose arrest, conviction, or adjudication of delinquency has been expunged pursuant to this subsection that their arrest, conviction, or adjudication of juvenile delinquency has been expunged, and the effect of such expungement.

(3) RIGHT TO PETITION COURT FOR EXPUNGEMENT.—At any point after the date of enactment of this Act, any individual with a prior conviction or adjudication of juvenile delinquency for a Federal cannabis offense, who is not under a criminal justice sentence, may file a motion for expungement. If the expungement of such a conviction or adjudication of juvenile delinquency is required pursuant to this Act, the court shall expunge the conviction or adjudication, and any associated arrests. If the individual is indigent, counsel shall be appointed to represent the individual in any proceedings under this subsection.

(4) SEALED RECORD.—The court shall seal all records related to a conviction or adjudication of juvenile delinquency that has been expunged under this subsection. Such records may only be made available by further order of the court.

(5) CERTIFICATION.—The court shall provide a certificate to the individual receiving expungement for a prior Federal cannabis offense. Any records of this certification shall be sealed under paragraph (4).

(b) Effect of expungement.—An individual who has had an arrest, a conviction, or juvenile delinquency adjudication expunged under this section—

(1) may treat the arrest, conviction, or adjudication as if it never occurred;

(2) shall be immune from any civil or criminal penalties related to perjury, false swearing, or false statements, for a failure to disclose such arrest, conviction, or adjudication; and

(3) shall not be subject to any loss of Federal benefits related to the expunged cannabis offense.

(c) Exception.—An individual who at sentencing received an aggravating role adjustment pursuant to section 3B1.1(a) of the United States Sentencing Guidelines in relation to a Federal cannabis offense conviction shall not be eligible for expungement of that Federal cannabis offense conviction under this section, unless a Federal court conducting the sentencing review finds mitigating factors to warrant expungement, including the age of the individual at the time of the arrest, conviction, or adjudication, the role of the individual in the offense, or whether it was the first Federal cannabis offense committed by the individual.

(d) Definitions.—In this section:

(1) The term “Federal cannabis offense” means an offense that is no longer punishable pursuant to this Act or the amendments made under this Act.

(2) The term “expunge” means, with respect to an arrest, a conviction, or a juvenile delinquency adjudication, the removal of the record of such arrest, conviction, or adjudication from each official index or public record.

(3) The term “under a criminal justice sentence” means, with respect to an individual, that the individual is serving a term of probation, parole, supervised release, imprisonment, official detention, pre-release custody, or work release, pursuant to a sentence or disposition of juvenile delinquency imposed on or after May 1, 1971.

(e) Study.—The Comptroller General of the United States, in consultation with the Secretary of Health and Human Services, shall conduct a demographic study of individuals convicted of a Federal cannabis offense. Such study shall include information about the age, race, ethnicity, sex, and gender identity of those individuals, the type of community such users dwell in, and such other demographic information as the Comptroller General determines should be included.

(f) Report.—Not later than 2 years after the date of the enactment of this Act, the Comptroller General of the United States shall report to Congress the results of the study conducted under subsection (f).

(a) In general.—No person may be denied any Federal public benefit (as such term is defined in section 401(c) of the Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (8 U.S.C. 1611(c))) on the basis of any use or possession of cannabis, or on the basis of a conviction or adjudication of juvenile delinquency for a cannabis offense, by that person.

(b) Security clearances.—A Federal agency may not grant, deny, or rescind a security clearance based solely on past or present cannabis use.

(a) In general.—For purposes of the immigration laws (as defined in section 101 of the Immigration and Nationality Act (8 U.S.C. 1101(a))), cannabis may not be considered a controlled substance, and an alien may not be denied any benefit or protection under the immigration laws based on any event, including conduct, a finding, an admission, addiction or abuse, an arrest, a juvenile adjudication, or a conviction, relating to cannabis, regardless of whether the event occurred before, on, or after the effective date of this Act.

(b) Amendments to the Immigration and Nationality Act.—The Immigration and Nationality Act (8 U.S.C. 1101 et seq.) is amended—

(1) in section 101(f)(3) (8 U.S.C. 1101(f)(3)), by striking “(except as such paragraph relates to a single offense of simple possession of 30 grams or less of marihuana)”;

(2) in section 210(c)(2)(B)(ii)(III) (8 U.S.C. 1160(c)(2)(B)(ii)(III)), by striking “, except for so much of such paragraph as relates to a single offense of simple possession of 30 grams or less of marihuana”;

(3) in section 212(h) (8 U.S.C. 1182(h)), by striking “and subparagraph (A)(i)(II) of such subsection insofar as it relates to a single offense of simple possession of 30 grams or less of marijuana”;

(4) in section 237(a)(2)(B)(i) (8 U.S.C. (a)(2)(B)(i)), by striking “, other than a single offense involving possession for one’s own use of 30 grams or less of marijuana”;

(5) in section 240(c)(6) (8 U.S.C. 1229a(c)(6)), by amending subparagraphs (A) and (B) to read as follows:

“(A) RIGHT TO FILE.—

“(i) IN GENERAL.—Except as provided in clause (ii), a noncitizen may file 1 motion to reconsider a decision that the alien is removable from the United States.

“(ii) REMOVAL ORDERS IMPACTED BY CANNABIS OFFENSES.—In addition to the motion authorized under clause (i), a removal order shall be reconsidered upon a motion filed at any time by a noncitizen demonstrating that—

“(I) such order was based, in whole or in part, on an offense relating to cannabis that rendered the noncitizen deportable or inadmissible; or

“(II) an offense relating to cannabis—

“(aa) rendered the noncitizen ineligible for a benefit or relief under this Act; or

“(bb) formed all or part of the basis for the denial of a benefit or relief under this Act.

“(B) DEADLINE.—A motion to reconsider under subparagraph (A)(i) shall be filed not later than 30 days after the date of entry of the relevant final administrative order of removal.”;

(6) in section 244(c)(2)(A)(iii)(II) (8 U.S.C. 1254a(c)(2)(A)(iii)(II)) by striking “, except for so much of such paragraph as relates to a single offense of simple possession of 30 grams or less of marijuana”;

(7) in section 245(h)(2)(B) (8 U.S.C. 1255(h)(2)(B)) by striking “(except for so much of such paragraph as related to a single offense of simple possession of 30 grams or less of marijuana)”; and

(8) in section 245A(d)(2)(B)(ii)(II) (8 U.S.C. 1255a(d)(2)(B)(ii)(II)) by striking “, except for so much of such paragraph as relates to a single offense of simple possession of 30 grams or less of marihuana”.

Not later than 180 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall update all applicable regulations, guidance, memoranda, and policies of the Department of Veterans Affairs to authorize physicians and other health care providers employed by the Department—

(1) to provide recommendations and opinions to veterans regarding the participation of such veterans in cannabis programs authorized under State or Federal law; and

(2) to complete forms reflecting such recommendations and opinions.

Not later than 180 days after the date of enactment of this Act, the Director of the Indian Health Service shall update all applicable regulations, guidance, memoranda, and policies of the Indian Health Service to authorize health care providers (as defined in section 805(a) of the Indian Health Care Improvement Act (25 U.S.C. 1675(a)))—

(1) to provide recommendations and opinions to patients relating to the participation of those patients in State or Tribal cannabis programs authorized under Federal or State law; and

(2) to complete forms reflecting those recommendations and opinions.

(a) Cannabis Revenue and Regulation Act.—Subtitle E of the Internal Revenue Code of 1986 is amended by adding at the end the following new chapter:

“Sec. 5901. Imposition of tax.
“Sec. 5902. Definitions.
“Sec. 5903. Liability and method of payment.
“Sec. 5904. Exemption from tax; transfers in bond.
“Sec. 5905. Credit, refund, or drawback of tax.

“Sec. 5911. Establishment and bond.
“Sec. 5912. Application.
“Sec. 5913. Cannabis production facility.

“Sec. 5921. Inventories, reports, and records.
“Sec. 5922. Packaging and labeling.
“Sec. 5923. Purchase, receipt, possession, or sale of cannabis products after removal.
“Sec. 5924. Restrictions relating to marks, labels, notices, and packages.
“Sec. 5925. Restriction on importation of previously exported cannabis products.

“Sec. 5931. Civil penalties.
“Sec. 5932. Criminal penalties.

(b) Establishment of trust fund.—Subchapter A of chapter 98 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:

(c) Study.—Not later than 2 years after the date of the enactment of this Act, and every 5 years thereafter, the Secretary of the Treasury, or the Secretary’s delegate, shall—

(1) conduct a study concerning the characteristics of the cannabis industry, including—

(A) the number of persons operating cannabis enterprises at each level of such industry,

(B) the volume of sales,

(C) the amount of tax collected each year,

(D) the areas of evasion, and

(E) the impact of disparate State taxes on diversion and smuggling of cannabis products, and

(2) submit to Congress recommendations to improve the regulation of the industry and the administration of the related tax.

(d) Annual reports regarding determination of applicable rates.—Not later than 6 months before the beginning of each calendar year to which section 5901(a)(2) of the Internal Revenue Code of 1986 (as added by this section) applies, the Secretary of the Treasury, or the Secretary’s delegate, shall make publicly available a detailed description of the methodology which the Secretary anticipates using to determine the applicable rate per ounce and the applicable rate per gram which will apply for such calendar year under section 5901(c)(2) of such Code.

(e) Drawback on tax for distilled spirits used in production of cannabis or hemp.—Section 5111 of the Internal Revenue Code of 1986 is amended by striking “or perfume” and inserting “perfume, cannabis products, or hemp-derived products”.

(f) Interest of internal revenue officer or employee in production of cannabis products.—Section 7214(b) of the Internal Revenue Code of 1986 is amended—

(1) in the heading, by striking “tobacco or liquor production” and inserting “production of tobacco, liquor, or cannabis products”, and

(2) by striking “or cigarettes” and inserting “cigarettes, or cannabis products (as defined in section 5902(a)(1))”.

(g) Papers, tubes, and wrappers.—Section 5702 of the Internal Revenue Code of 1986 is amended—

(1) in subsection (e)—

(A) by inserting “or a cannabis product” after “tobacco”, and

(B) by inserting “(including for use as a cannabis cigarette wrapper)” after “cigarette wrapper”,

(2) in subsection (f), by inserting “(including for use in making cannabis cigarettes)” after “making cigarettes”, and

(3) in subsection (o), by inserting “(including for use in making cannabis cigarettes)” after “wrapper thereof”.

(h) Conforming amendments.—

(1) Section 6103(o)(1)(A) of the Internal Revenue Code of 1986 is amended by striking “and firearms” and inserting “firearms, and cannabis products”.

(2) The heading of subsection (a) of section 7608 of such Code is amended by inserting “cannabis products,” after “tobacco,”.

(3) The table of chapters for subtitle E of such Code is amended by adding at the end the following new item:

(4) The table of sections for subchapter A of chapter 98 of such Code is amended by adding at the end the following new item:

“Sec. 9512. Opportunity Trust Fund.”.

(i) Effective date.—

(1) IN GENERAL.—Except as otherwise provided in this subsection, the amendments made by this section shall apply to removals, and applications under section 5912 of the Internal Revenue Code of 1986 (as added by subsection (a)), after 180 days after the date of the enactment of this Act.

(2) OTHER AMENDMENTS.—The amendments made by subsections (b), (c), (d), (f), (g), and (h) shall take effect on the date of the enactment of this Act.

(a) In general.—The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is amended by adding at the end the following:

(a) Definitions.—Section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321) is amended—

(1) in paragraph (g)(1)(C), by striking “(other than food)” and inserting “(other than food or cannabis products)”;

(2) in paragraph (ff)(1), by striking “(other than tobacco)” and inserting “(other than a tobacco product or cannabis product)”;

(3) in paragraph (rr)(4), by inserting “cannabis product,” after “medical device”; and

(4) by adding at the end the following:

“(ss) (1) (A) The term ‘cannabis’ means—

“(i) all parts of the plant Cannabis sativa L., whether growing or not;

“(ii) the seeds thereof;

“(iii) the resin extracted from any part of such plant; and

“(iv) every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin.

“(B) The term ‘cannabis’ does not include—

“(i) hemp, as defined in section 297A of the Agricultural Marketing Act of 1946; or

“(ii) the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination.

“(2) (A) The term ‘cannabis product’ means any product made or derived from cannabis that is intended for consumption or applied to the body of man or other animals, including any component of such product.

“(B) A ‘cannabis product’ does not mean an article that is a drug within the meaning of paragraph (g)(1).

“(3) With respect to cannabis or a cannabis product, the term ‘manufacture’ includes the planting, cultivation, growing, and harvesting of cannabis.”.

(b) Prohibited acts.—Section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amended—

(1) by inserting “cannabis product,” after “tobacco product,” each place it appears in paragraphs (g) and (h);

(2) in paragraph (j), by striking “or 920(b)” and inserting “920(b), or 1104”;

(3) in paragraph (p)—

(A) by striking “510 or 905” and inserting “510, 905, or 1104”;

(B) by striking “or 905(j)” and inserting “905(j), or 1104(g)”; and

(C) by striking “or 905(i)(3)” and inserting “, 905(i)(3), or 1104(g)(2)”;

(4) in paragraph (q)(2) by inserting “, cannabis product,” after “device”;

(5) in paragraph (r), by inserting “cannabis product,” after “device,” each place it appears; and

(6) by adding at the end the following:

“(fff) (1) The sale or distribution of a cannabis product to any person younger than 21 years of age.

“(2) The sale or distribution, in any retail single transaction, of more than 10 ounces of any cannabis product.

“(3) The sale or distribution of an article that is a cannabis product and that contains alcohol, caffeine, or nicotine.

“(4) The failure of a manufacturer or distributor to notify the Attorney General and the Secretary of the Treasury of its knowledge of cannabis products used in illicit trade.

“(ggg) (1) The introduction or delivery for introduction into commerce of any cannabis product that is adulterated or misbranded.

“(2) The adulteration or misbranding of any cannabis product in commerce.

“(3) The receipt in commerce of any cannabis product that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise.

“(4) The alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the labeling of, or the doing of any other act with respect to a cannabis product, if such act is done while such article is held for sale (whether or not the first sale) after shipment in commerce and results in such article being adulterated or misbranded.

“(hhh) The failure to comply with the requirements of section 524C.”.

(c) Seizure authorities.—Section 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 334) is amended—

(1) in subsection (a)—

(A) in paragraph (1), by inserting “cannabis product,” after “drug,”; and

(B) in paragraph (2), by inserting “or cannabis product” after “tobacco product”;

(2) in subsection (d)(1), by inserting “cannabis product,” after “tobacco product,”; and

(3) in subsection (g), by striking “or tobacco product” each place it appears in paragraphs (1) and (2)(A) and inserting “, tobacco product, or cannabis product”.

(d) Factory inspection.—Section 704 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374) is amended—

(1) in subsection (a)—

(A) by inserting “cannabis products,” after “tobacco products,” each place it appears;

(B) by striking “or tobacco products” each place it appears and inserting “tobacco products, or cannabis products”; and

(C) by striking “and tobacco products” and inserting “tobacco products, and cannabis products”; and

(2) in subsection (b)(1), by inserting “cannabis product,” after “tobacco product,”.

(e) Publicity.—Section 705(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 375(b)) is amended by inserting “cannabis products,” after “tobacco products,”.

(f) Presumption.—Section 709 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379a) is amended by inserting “cannabis product,” after “tobacco product,”.

(g) Imports and exports.—Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) is amended—

(1) in subsection (a)—

(A) by inserting “cannabis products,” after “tobacco products,”;

(B) by striking “or tobacco products” each place it appears and inserting “, tobacco products, or cannabis products”; and

(C) by striking “or section 905(h)” and inserting “, 905(h), or 1104”; and

(2) in subsection (e), by striking “tobacco product or” and inserting “tobacco product, cannabis product, or”.

Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by adding at the end the following:

(a) CBD as a dietary supplement.—Section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(ff)(3)(B)) is amended, in the matter preceding subclause (i), by inserting “, except in the case of cannabidiol derived from hemp (as defined in section 297A of the Agricultural Marketing Act of 1946)” after “include”.

(b) Adulteration.—Section 402 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 342) is amended by adding at the end the following new subsection:

“(j) (1) If it is a dietary supplement that contains cannabidiol, unless—

“(A) such dietary supplement contains no more than an amount of cannabidiol per recommended daily serving that the Secretary may establish (and revise or repeal as appropriate), subject to paragraph (2), through an interim final rule, notwithstanding any requirement for notice and comment that may otherwise apply under section 553 of title 5, United States Code;

“(B) such dietary supplement is the subject of a notification submitted to the Secretary in accordance with section 413(a)(2); and

“(C) the labeling and packaging of such dietary supplement conforms with any requirements that the Secretary establishes regarding labeling or packaging of dietary supplements containing cannabidiol (which may be promulgated (and revised or repealed as appropriate) by the Secretary through an interim final rule, notwithstanding any requirement for notice and comment that may otherwise apply under section 553 of title 5, United States Code).

“(2) (A) The amount of cannabidiol established in accordance with paragraph (1)(A)—

“(i) shall be a threshold above which the Secretary may not accept new dietary ingredient notifications; and

“(ii) shall not be interpreted as a determination that lower amounts of cannabidiol are safe.

“(B) The Secretary shall establish such a threshold based on such factors as the Secretary determines to be appropriate, which may include a consideration of whether the review of new dietary ingredient notifications for products containing higher levels of cannabidiol may be unduly burdensome.”.

(c) New dietary ingredient.—Section 413(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 350b(a)(1)) is amended by inserting “contains no cannabidiol and” before “contains only dietary ingredients”.

(d) New prohibited act.—Section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331), as amended by section 502(b)(6), is further amended by adding at the end the following:

“(iii) The introduction or delivery for introduction into interstate commerce of any product labeled as a dietary supplement that fails to meet the definition of a dietary supplement under section 201(ff).”.

(e) New import exclusion.—Section 801(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381(a)) is amended in paragraph (3) of the third sentence by striking “section 301(ll)” and inserting “paragraph (ll) or (iii) of section 301”.

(f) New seizure authorities.—Section 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 334) is amended—

(1) in subsection (a)(1), in the first sentence, by inserting “or any article which may not be introduced or delivered for introduction into interstate commerce under section 301(iii),” before “shall be liable”; and

(2) in subsection (d)(1), in the first sentence, by inserting “, or any product otherwise introduced or delivered for introduction into interstate commerce in violation of section 301(iii) and condemned under this section,” after “under this section”.

(g) CBD as a food additive.—

(1) IN GENERAL.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) shall issue draft guidance describing criteria by which the Secretary intends to evaluate the safety of cannabidiol as a food additive in any food additive petition under section 409 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 348). The Secretary shall publish final guidance within 180 days of the close of the public comment period on such draft guidance.

(2) ADVISORY COMMITTEE.—Before issuing draft guidance under paragraph (1), the Secretary shall convene and consult an advisory committee, which shall include experts qualified in the subject matter.

(a) Transition period for cannabis products.—With respect to a cannabis product that was marketed in the United States within 30 days of the date of enactment of this Act pursuant to a State law permitting the marketing of such product, such product shall not be considered to be in violation of chapter XI of the Federal Food, Drug, and Cosmetic Act (as added by section 501) or section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331), as amended by this title, as applicable, during the 18-month period following the date of enactment of this Act.

(b) Submission of applications for previously marketed drugs containing cannabis.—

(1) TRANSITION PERIOD FOR DRUGS CONTAINING CANNABIS.—With respect to a drug containing cannabis that was being marketed in the United States within 30 days after the date of enactment of this Act pursuant to a State law permitting cannabis for medical use, such drug shall not be considered to be in violation of chapter V or section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331; 351 et seq.) during the 3-year period following the date of enactment of this Act.

(2) SUBMISSION OF APPLICATIONS.—

(A) IN GENERAL.—As a condition for continuing to market a drug described in paragraph (1) during the 3-year period specified in such paragraph, during the 18-month period beginning on the effective date of this Act, the manufacturer shall submit a new drug application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S. C. 355(b)) for such drug.

(B) TRANSITION PERIOD.—Except as provided in subparagraph (C), with respect to a drug containing cannabis for which an application is submitted as described in subparagraph (A), the manufacturer of such product may continue to market such drug in the State described in paragraph (1) during the 3-year period beginning on the effective date of this Act.

(C) EXCEPTION.—If the Secretary of Health and Human Services issues an order refusing to approve an application under section 505(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(d)) for a drug that contains cannabis, such drug shall not be eligible for continued marketing under subparagraph (B).

(3) END OF TRANSITION PERIOD.—Beginning on the date that is 3 years after the date of enactment of this Act the Secretary may take enforcement action, as appropriate, for a drug described in paragraph (1) (including such a drug that is the subject of a pending application under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)) found to be in violation of chapter V or section 301 of the Federal Food, Drug, and Cosmetic Act.

(4) RULE OF CONSTRUCTION.—Nothing in this subsection shall be construed to prohibit the marketing of a cannabis product otherwise in compliance with relevant provisions of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.).

(c) Definition.—For purposes of this section, the term “drug containing cannabis” means any drug that contains any article made or derived from cannabis.

Section 2(2)(B) of the Poison Prevention Packaging Act of 1970 (15 U.S.C. 1471(2)(B)) is amended by striking “or cosmetic” and inserting “cosmetic, or cannabis product,”.

In addition to amounts otherwise available, there is appropriated, out of any funds in the Treasury not otherwise appropriated, $425,000,000 for each of fiscal years 2023 through 2027 to carry out this title and the amendments made by this title.

(a) In general.—The Federal Alcohol Administration Act (27 U.S.C. 201 et seq.) is amended by adding at the end the following: